Vitespen Failed To Improve Remission After Kidney Tumor-Removing Surgery
Friday, July 4th, 2008The British Journal The Lancet has reported that a new kidney cancer vaccine called vitespen, failed in last-phase clinical trials to improve the odds of avoiding remission after tumor-removing surgery. Christopher Wood and other of his co researchers of the Anderson Cancer Center in Houston, have tested the vaccine to 409 patients whose [...]
